Comparison of fractional exhaled nitric oxide levels in chronic obstructive pulmonary disease, bronchial asthma and healthy subjects of Nepal

Shrestha, Sanjeet Krishna; Shrestha, Sanjeev; Sharma, Lucky; Pant, Subash; Neopane, A

doi:10.1088/1752-7163/aa7e63

Cited by 11 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Takayama [ 28 ] showed that COPD patients without treatment can be diagnosed as having ACO when the FeNO level is ≥ 25 ppb. In this study, patients with ACO had higher FeNO levels than those with COPD, but FeNO had no value in predicting ACO from COPD, which was inconsistent with previous studies’ findings [ 38 , 44 ]. This result is likely due to the fact that patients had a positive BDT result, which can weaken the difference of the FeNO level between ACO and COPD.…”

Section: Discussioncontrasting

confidence: 99%

“…However, there was no difference in BECs among the asthma, COPD, and ACO groups in the real-world study cohort, NOVELTY [ 6 ]. Additionally, patients with asthma and those with ACO had higher FeNO levels than those with COPD, which is similar to previous studies’ results [ 38 , 39 ]. Therefore, BDR combined with the biomarkers of type 2 airway inflammation may be a useful tool in distinguishing between COPD and ACO or asthma.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

The value of bronchodilator response in FEV1 and FeNO for differentiating between chronic respiratory diseases: an observational study

Gong,

Huang,

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

Background There is no uniform standard for a strongly positive bronchodilation test (BDT) result. In addition, the role of bronchodilator response in differentiating between asthma, chronic obstructive pulmonary disease (COPD), and asthma–COPD overlap (ACO) in patients with a positive BDT result is unclear. We explored a simplified standard of a strongly positive BDT result and whether bronchodilator response combined with fractional exhaled nitric oxide (FeNO) can differentiate between asthma, COPD, and ACO in patients with a positive BDT result. Methods Three standards of a strongly positive BDT result, which were, respectively, defined as post-bronchodilator forced expiratory volume in 1-s responses (ΔFEV1) increasing by at least 400 mL + 15% (standard I), 400 mL (standard II), or 15% (standard III), were analyzed in asthma, COPD, and ACO patients with a positive BDT result. Receiver operating characteristic curves were used to determine the optimal values of ΔFEV1 and FeNO. Finally, the accuracy of prediction was verified by a validation study. Results The rates of a strongly positive BDT result and the characteristics between standards I and II were consistent; however, those for standard III was different. ΔFEV1 ≥ 345 mL could predict ACO diagnosis in COPD patients with a positive BDT result (area under the curve [AUC]: 0.881; 95% confidence interval [CI] 0.83–0.94), with a sensitivity and specificity of 90.0% and 91.2%, respectively, in the validation study. When ΔFEV1 was < 315 mL combined with FeNO < 28.5 parts per billion, patients with a positive BDT result were more likely to have pure COPD (AUC: 0.774; 95% CI 0.72–0.83). Conclusion The simplified standard II can replace standard I. ΔFEV1 and FeNO are helpful in differentiating between asthma, COPD, and ACO in patients with a positive BDT result.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Discussionsupporting

confidence: 91%

The value of bronchodilator response in FEV1 and FeNO for differentiating between chronic respiratory diseases: an observational study

Gong,

Huang,

et al. 2024

Eur J Med Res

View full text Add to dashboard Cite

show abstract

“…The sample size across studies varied from 21 to 212, with a total number of 1,669. The majority of studies were from Europe,10–12,15,18–20,22,23,26–30,33 with 1 study from Australia,17 1 study from America,13 2 studies from Africa,21,32 and 5 studies from Asia 14,16,24,25,31. In terms of diagnosis of COPD, 9 studies used doctor-diagnosis,13,15,17,21,23,29,31,32 8 studies used GOLD guideline,10,12,14,18,22,24,26,30,33 2 applied American Thoracic Society criteria,11,16 2 applied European Respiratory Society criteria,20,27 2 applied British Thoracic Society guidelines,19,28 and 1 applied Chinese Medical Association guidelines 25…”

Section: Resultsmentioning

confidence: 99%

Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

Lu¹,

Huang²,

Wang³

et al. 2018

COPD

View full text Add to dashboard Cite

BackgroundFractional exhaled nitric oxide (FENO) is a useful and noninvasive biomarker for eosinophilic airway inflammation, particularly in asthma. However, its utility in chronic obstructive pulmonary disease (COPD) remains controversial. In this study, we performed a systematic review and meta-analysis to evaluate FENO levels in COPD.MethodsA search of PubMed, Embase, Cochrane Library, and clinical trial registry was conducted from inception to January 2018. Studies were included if they reported FENO levels in patients with COPD and healthy controls. We then extracted relevant information and analyzed data. Standard mean difference (SMD) with 95% confidence interval (CI) was applied in this meta-analysis.ResultsA total of 2,073 studies were reviewed for eligibility, with 24 studies pooled for analysis. The FENO levels in patients with COPD were elevated mildly compared with healthy controls (SMD 1.28, 95% CI 0.60–1.96). A similar result was also observed in stable COPD, with an SMD of 1.21 (95% CI 0.47–1.96). On the other hand, we found no association between FENO levels and exacerbated COPD. Additionally, for patients with COPD, ex-smokers had higher levels of FENO than current smokers (SMD 2.05, 95% CI 1.13–2.97).ConclusionOur studies demonstrated a mild elevation of FENO in COPD, and the association between exacerbated COPD and FENO levels needs to be further explored. The potential mechanism is still unknown and conflicting.

show abstract

“…A comparison of different mathematical methods to calculate NO parameters is also presented (Karvonen et al [17]). The widespread knowledge of the use of exhaled NO is found in an article from Nepal (Shrestha et al [18]) and in a perspective of exhaled nitric oxide (Ricciardolo & Silkoff [19]). Lars Gustafsson's contributions have had a marked and lasting impact on the field of exhaled breath analysis, particularly NO.…”

Section: Jon Lundberg Professor At the Karolinska Institutementioning

confidence: 99%

The unique contribution of Professor Lars E Gustafsson to the field of breath research

Högman

Risby

2017

J. Breath Res.

View full text Add to dashboard Cite

This special issue of the Journal of Breath Research is dedicated to Professor Lars E Gustafsson of the Karolinska Institute. Lars Gustafsson holds a special place in the history of the field of breath research because of his 1991 studies that identified nitric oxide in breath. These novel findings, coupled with nitric oxide being named 'Molecule of the Year' in 1992 by the journal Science [1] and the award of the 1998 Nobel Prize in Physiology and Medicine to Furchgott, Ignarro and Murad 'for the discoveries concerning nitric oxide as a signaling molecule in the cardiovascular system', drew the attention of clinicians to the potential use of breath analysis in diagnostic medicine. Before this time, breath analysis was viewed as an academic research area. A demonstration of the clinical interest for breath research was the organization of the first international conference on Disease Markers in Exhaled Breath: Basic Mechanisms and Clinical Applications by a group of clinicians (Marczin, Yacoub and Barnes) in 2001. The proceedings of this conference were subsequently

show abstract

Comparison of fractional exhaled nitric oxide levels in chronic obstructive pulmonary disease, bronchial asthma and healthy subjects of Nepal

Abstract: FNO levels were higher in bronchial asthma (despite disease control) than in normal non-smoking adults and subjects with stable chronic obstructive pulmonary disease. Levels of FNO were similar between the chronic obstructive airway disease and normal groups.

Cited by 11 publications

References 17 publications

The value of bronchodilator response in FEV1 and FeNO for differentiating between chronic respiratory diseases: an observational study

The value of bronchodilator response in FEV1 and FeNO for differentiating between chronic respiratory diseases: an observational study

Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis

The unique contribution of Professor Lars E Gustafsson to the field of breath research

Contact Info

Product

Resources

About